List of Tables
    Table 1. Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size United States VS Global, CAGR (2017 VS 2022 VS 2028)
    Table 2. Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Trends
    Table 3. Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Drivers
    Table 4. Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Challenges
    Table 5. Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Restraints
    Table 6. Global Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size by Type: 2017 VS 2022 VS 2028 (US$ Million)
    Table 7. United States Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size by Type: 2017 VS 2022 VS 2028 (US$ Million)
    Table 8. Global Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size by Application: 2017 VS 2022 VS 2028 (US$ Million)
    Table 9. United States Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size by Application: 2017 VS 2022 VS 2028 (US$ Million)
    Table 10. Top Non-Peptide Drugs of Angiotensin II Receptor Antagonist Companies in Global Market, Ranking by Revenue (2021)
    Table 11. Global Non-Peptide Drugs of Angiotensin II Receptor Antagonist Revenue by Player, (US$ Million), 2017-2022
    Table 12. Global Non-Peptide Drugs of Angiotensin II Receptor Antagonist Revenue Share by Player, 2017-2022
    Table 13. Global Non-Peptide Drugs of Angiotensin II Receptor Antagonist Companies Market Concentration Ratio (CR5 and HHI)
    Table 14. Global Non-Peptide Drugs of Angiotensin II Receptor Antagonist by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Non-Peptide Drugs of Angiotensin II Receptor Antagonist as of 2021)
    Table 15. Top Players of Non-Peptide Drugs of Angiotensin II Receptor Antagonist in Global Market, Headquarters and Area Served
    Table 16. Companies Revenue in Non-Peptide Drugs of Angiotensin II Receptor Antagonist Business (2017-2022) & (US$ Million) Type
    Table 17. Date of International Companies Enter into Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market
    Table 18. Companies Mergers & Acquisitions, Expansion Plans
    Table 19. Top Non-Peptide Drugs of Angiotensin II Receptor Antagonist Players in United States Market, Ranking by Revenue (2021)
    Table 20. United States Non-Peptide Drugs of Angiotensin II Receptor Antagonist Revenue by Players, (US$ Million), 2020, 2021 & 2022
    Table 21. United States Non-Peptide Drugs of Angiotensin II Receptor Antagonist Revenue Share by Players, 2020, 2021 & 2022
    Table 22. Global Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size by Region (US$ Million): 2017 VS 2022 VS 2028
    Table 23. Global Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size by Region (2017-2022) & (US$ Million)
    Table 24. Global Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size Forecast by Region (2023-2028) & (US$ Million)
    Table 25. North America Non-Peptide Drugs of Angiotensin II Receptor Antagonist Sales in Value by Country (2017-2028) & (US$ Million)
    Table 26. Asia Pacific Non-Peptide Drugs of Angiotensin II Receptor Antagonist Sales in Value by Region (2017-2028) & (US$ Million)
    Table 27. Europe Non-Peptide Drugs of Angiotensin II Receptor Antagonist Sales in Value by Country (2017-2028) & (US$ Million)
    Table 28. Latin Americaa Non-Peptide Drugs of Angiotensin II Receptor Antagonist Sales in Value by Country (2017-2028) & (US$ Million)
    Table 29. Middle East and Africa Non-Peptide Drugs of Angiotensin II Receptor Antagonist Sales in Value by Country (2017-2028) & (US$ Million)
    Table 30. Pfizer Company Details
    Table 31. Pfizer Business Overview
    Table 32. Pfizer Non-Peptide Drugs of Angiotensin II Receptor Antagonist Product
    Table 33. Pfizer Revenue in Non-Peptide Drugs of Angiotensin II Receptor Antagonist Business (2017-2022) & (US$ Million)
    Table 34. Pfizer Recent Development
    Table 35. Novartis Company Details
    Table 36. Novartis Business Overview
    Table 37. Novartis Non-Peptide Drugs of Angiotensin II Receptor Antagonist Product
    Table 38. Novartis Revenue in Non-Peptide Drugs of Angiotensin II Receptor Antagonist Business (2017-2022) & (US$ Million)
    Table 39. Novartis Recent Development
    Table 40. Merck Company Details
    Table 41. Merck Business Overview
    Table 42. Merck Non-Peptide Drugs of Angiotensin II Receptor Antagonist Product
    Table 43. Merck Revenue in Non-Peptide Drugs of Angiotensin II Receptor Antagonist Business (2017-2022) & (US$ Million)
    Table 44. Merck Recent Development
    Table 45. AstraZeneca Company Details
    Table 46. AstraZeneca Business Overview
    Table 47. AstraZeneca Non-Peptide Drugs of Angiotensin II Receptor Antagonist Product
    Table 48. AstraZeneca Revenue in Non-Peptide Drugs of Angiotensin II Receptor Antagonist Business (2017-2022) & (US$ Million)
    Table 49. AstraZeneca Recent Development
    Table 50. Jhonson and Johnson Company Details
    Table 51. Jhonson and Johnson Business Overview
    Table 52. Jhonson and Johnson Non-Peptide Drugs of Angiotensin II Receptor Antagonist Product
    Table 53. Jhonson and Johnson Revenue in Non-Peptide Drugs of Angiotensin II Receptor Antagonist Business (2017-2022) & (US$ Million)
    Table 54. Jhonson and Johnson Recent Development
    Table 55. Eli Lilly Company Details
    Table 56. Eli Lilly Business Overview
    Table 57. Eli Lilly Non-Peptide Drugs of Angiotensin II Receptor Antagonist Product
    Table 58. Eli Lilly Revenue in Non-Peptide Drugs of Angiotensin II Receptor Antagonist Business (2017-2022) & (US$ Million)
    Table 59. Eli Lilly Recent Development
    Table 60. Sanofi Company Details
    Table 61. Sanofi Business Overview
    Table 62. Sanofi Non-Peptide Drugs of Angiotensin II Receptor Antagonist Product
    Table 63. Sanofi Revenue in Non-Peptide Drugs of Angiotensin II Receptor Antagonist Business (2017-2022) & (US$ Million)
    Table 64. Sanofi Recent Development
    Table 65. Bristol-Myers Squibb Company Details
    Table 66. Bristol-Myers Squibb Business Overview
    Table 67. Bristol-Myers Squibb Non-Peptide Drugs of Angiotensin II Receptor Antagonist Product
    Table 68. Bristol-Myers Squibb Revenue in Non-Peptide Drugs of Angiotensin II Receptor Antagonist Business (2017-2022) & (US$ Million)
    Table 69. Bristol-Myers Squibb Recent Development
    Table 70. Bayer Company Details
    Table 71. Bayer Business Overview
    Table 72. Bayer Non-Peptide Drugs of Angiotensin II Receptor Antagonist Product
    Table 73. Bayer Revenue in Non-Peptide Drugs of Angiotensin II Receptor Antagonist Business (2017-2022) & (US$ Million)
    Table 74. Bayer Recent Development
    Table 75. GSK Company Details
    Table 76. GSK Business Overview
    Table 77. GSK Non-Peptide Drugs of Angiotensin II Receptor Antagonist Product
    Table 78. GSK Revenue in Non-Peptide Drugs of Angiotensin II Receptor Antagonist Business (2017-2022) & (US$ Million)
    Table 79. GSK Recent Development
    Table 80. Teva Pharmaceutical Company Details
    Table 81. Teva Pharmaceutical Business Overview
    Table 82. Teva Pharmaceutical Non-Peptide Drugs of Angiotensin II Receptor Antagonist Product
    Table 83. Teva Pharmaceutical Revenue in Non-Peptide Drugs of Angiotensin II Receptor Antagonist Business (2017-2022) & (US$ Million)
    Table 84. Teva Pharmaceutical Recent Development
    Table 85. Shenzhen Salubris Pharmaceuticals  Company Details
    Table 86. Shenzhen Salubris Pharmaceuticals  Business Overview
    Table 87. Shenzhen Salubris Pharmaceuticals  Non-Peptide Drugs of Angiotensin II Receptor Antagonist Product
    Table 88. Shenzhen Salubris Pharmaceuticals  Revenue in Non-Peptide Drugs of Angiotensin II Receptor Antagonist Business (2017-2022) & (US$ Million)
    Table 89. Shenzhen Salubris Pharmaceuticals  Recent Development
    Table 90. Sun Pharmaceutical Company Details
    Table 91. Sun Pharmaceutical Business Overview
    Table 92. Sun Pharmaceutical Non-Peptide Drugs of Angiotensin II Receptor Antagonist Product
    Table 93. Sun Pharmaceutical Revenue in Non-Peptide Drugs of Angiotensin II Receptor Antagonist Business (2017-2022) & (US$ Million)
    Table 94. Sun Pharmaceutical Recent Development
    Table 95. Mylan Company Details
    Table 96. Mylan Business Overview
    Table 97. Mylan Non-Peptide Drugs of Angiotensin II Receptor Antagonist Product
    Table 98. Mylan Revenue in Non-Peptide Drugs of Angiotensin II Receptor Antagonist Business (2017-2022) & (US$ Million)
    Table 99. Mylan Recent Development
    Table 100. Alembic Pharmaceuticals Company Details
    Table 101. Alembic Pharmaceuticals Business Overview
    Table 102. Alembic Pharmaceuticals Non-Peptide Drugs of Angiotensin II Receptor Antagonist Product
    Table 103. Alembic Pharmaceuticals Revenue in Non-Peptide Drugs of Angiotensin II Receptor Antagonist Business (2017-2022) & (US$ Million)
    Table 104. Alembic Pharmaceuticals Recent Development
    Table 105. Lupin Company Details
    Table 106. Lupin Business Overview
    Table 107. Lupin Non-Peptide Drugs of Angiotensin II Receptor Antagonist Product
    Table 108. Lupin Revenue in Non-Peptide Drugs of Angiotensin II Receptor Antagonist Business (2017-2022) & (US$ Million)
    Table 109. Lupin Recent Development
    Table 110. Aurobindo Pharma Company Details
    Table 111. Aurobindo Pharma Business Overview
    Table 112. Aurobindo Pharma Non-Peptide Drugs of Angiotensin II Receptor Antagonist Product
    Table 113. Aurobindo Pharma Revenue in Non-Peptide Drugs of Angiotensin II Receptor Antagonist Business (2017-2022) & (US$ Million)
    Table 114. Aurobindo Pharma Recent Development
    Table 115. Amneal Pharmaceuticals Company Details
    Table 116. Amneal Pharmaceuticals Business Overview
    Table 117. Amneal Pharmaceuticals Non-Peptide Drugs of Angiotensin II Receptor Antagonist Product
    Table 118. Amneal Pharmaceuticals Revenue in Non-Peptide Drugs of Angiotensin II Receptor Antagonist Business (2017-2022) & (US$ Million)
    Table 119. Amneal Pharmaceuticals Recent Development
    Table 120. Boehringer Ingelheim Company Details
    Table 121. Boehringer Ingelheim Business Overview
    Table 122. Boehringer Ingelheim Non-Peptide Drugs of Angiotensin II Receptor Antagonist Product
    Table 123. Boehringer Ingelheim Revenue in Non-Peptide Drugs of Angiotensin II Receptor Antagonist Business (2017-2022) & (US$ Million)
    Table 124. Boehringer Ingelheim Recent Development
    Table 125. Research Programs/Design for This Report
    Table 126. Key Data Information from Secondary Sources
    Table 127. Key Data Information from Primary Sources
List of Figures
    Figure 1. Non-Peptide Drugs of Angiotensin II Receptor Antagonist Product Picture
    Figure 2. Global Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size, (US$ Million), 2017 VS 2022 VS 2028
    Figure 3. Global Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size 2017-2028 (US$ Million)
    Figure 4. United States Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size, (US$ Million), 2017 VS 2022 VS 2028
    Figure 5. United States Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size 2017-2028 (US$ Million)
    Figure 6. United States Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Share in Global 2017-2028
    Figure 7. Non-Peptide Drugs of Angiotensin II Receptor Antagonist Report Years Considered
    Figure 8. Product Picture of Valsartan
    Figure 9. Product Picture of Irbesartan
    Figure 10. Product Picture of Candesartan Cilexetil
    Figure 11. Product Picture of Eprosartan
    Figure 12. Product Picture of Irbesartan
    Figure 13. Product Picture of Telmisartan
    Figure 14. Product Picture of losartan
    Figure 15. Product Picture of Olmesartan Medoxomil
    Figure 16. Product Picture of Allisartan isoproxil
    Figure 17. Global Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Share by Type in 2022 & 2028
    Figure 18. Global Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size by Type (2017-2028) & (US$ Million)
    Figure 19. Global Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Share by Type (2017-2028)
    Figure 20. United States Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Share by Type in 2022 & 2028
    Figure 21. United States Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size by Type (2017-2028) & (US$ Million)
    Figure 22. United States Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Share by Type (2017-2028)
    Figure 23. Product Picture of High Blood Pressure
    Figure 24. Product Picture of Congestive Heart Failure
    Figure 25. Product Picture of Left Ventricular Hypertrophy
    Figure 26. Product Picture of Atherosclerosis
    Figure 27. Product Picture of Other
    Figure 28. Global Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Share by Application in 2022 & 2028
    Figure 29. Global Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size by Application (2017-2028) & (US$ Million)
    Figure 30. Global Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Share by Application (2017-2028)
    Figure 31. United States Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Share by Application in 2022 & 2028
    Figure 32. United States Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size by Application (2017-2028) & (US$ Million)
    Figure 33. United States Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Share by Application (2017-2028)
    Figure 34. North America Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size Growth Rate 2017-2028 (US$ Million)
    Figure 35. U.S. Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size Growth Rate (2017-2028) & (US$ Million)
    Figure 36. Canada Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size Growth Rate (2017-2028) & (US$ Million)
    Figure 37. Europe Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size Growth Rate 2017-2028 (US$ Million)
    Figure 38. Germany Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size Growth Rate (2017-2028) & (US$ Million)
    Figure 39. France Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size Growth Rate (2017-2028) & (US$ Million)
    Figure 40. U.K. Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size Growth Rate (2017-2028) & (US$ Million)
    Figure 41. Italy Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size Growth Rate (2017-2028) & (US$ Million)
    Figure 42. Russia Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size Growth Rate (2017-2028) & (US$ Million)
    Figure 43. Asia-Pacific Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size Growth Rate 2017-2028 (US$ Million)
    Figure 44. China Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size Growth Rate (2017-2028) & (US$ Million)
    Figure 45. Japan Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size Growth Rate (2017-2028) & (US$ Million)
    Figure 46. South Korea Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size Growth Rate (2017-2028) & (US$ Million)
    Figure 47. India Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size Growth Rate (2017-2028) & (US$ Million)
    Figure 48. Australia Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size Growth Rate (2017-2028) & (US$ Million)
    Figure 49. Taiwan Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size Growth Rate (2017-2028) & (US$ Million)
    Figure 50. Indonesia Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size Growth Rate (2017-2028) & (US$ Million)
    Figure 51. Thailand Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size Growth Rate (2017-2028) & (US$ Million)
    Figure 52. Malaysia Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size Growth Rate (2017-2028) & (US$ Million)
    Figure 53. Philippines Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size Growth Rate (2017-2028) & (US$ Million)
    Figure 54. Latin America Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size Growth Rate 2017-2028 (US$ Million)
    Figure 55. Mexico Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size Growth Rate (2017-2028) & (US$ Million)
    Figure 56. Brazil Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size Growth Rate (2017-2028) & (US$ Million)
    Figure 57. Argentina Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size Growth Rate (2017-2028) & (US$ Million)
    Figure 58. Middle East & Africa Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size Growth Rate 2017-2028 (US$ Million)
    Figure 59. Turkey Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size Growth Rate (2017-2028) & (US$ Million)
    Figure 60. Saudi Arabia Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size Growth Rate (2017-2028) & (US$ Million)
    Figure 61. U.A.E Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size Growth Rate (2017-2028) & (US$ Million)
    Figure 62. Pfizer Revenue Growth Rate in Non-Peptide Drugs of Angiotensin II Receptor Antagonist Business (2017-2022)
    Figure 63. Novartis Revenue Growth Rate in Non-Peptide Drugs of Angiotensin II Receptor Antagonist Business (2017-2022)
    Figure 64. Merck Revenue Growth Rate in Non-Peptide Drugs of Angiotensin II Receptor Antagonist Business (2017-2022)
    Figure 65. AstraZeneca Revenue Growth Rate in Non-Peptide Drugs of Angiotensin II Receptor Antagonist Business (2017-2022)
    Figure 66. Jhonson and Johnson Revenue Growth Rate in Non-Peptide Drugs of Angiotensin II Receptor Antagonist Business (2017-2022)
    Figure 67. Eli Lilly Revenue Growth Rate in Non-Peptide Drugs of Angiotensin II Receptor Antagonist Business (2017-2022)
    Figure 68. Sanofi Revenue Growth Rate in Non-Peptide Drugs of Angiotensin II Receptor Antagonist Business (2017-2022)
    Figure 69. Bristol-Myers Squibb Revenue Growth Rate in Non-Peptide Drugs of Angiotensin II Receptor Antagonist Business (2017-2022)
    Figure 70. Bayer Revenue Growth Rate in Non-Peptide Drugs of Angiotensin II Receptor Antagonist Business (2017-2022)
    Figure 71. GSK Revenue Growth Rate in Non-Peptide Drugs of Angiotensin II Receptor Antagonist Business (2017-2022)
    Figure 72. Teva Pharmaceutical Revenue Growth Rate in Non-Peptide Drugs of Angiotensin II Receptor Antagonist Business (2017-2022)
    Figure 73. Shenzhen Salubris Pharmaceuticals  Revenue Growth Rate in Non-Peptide Drugs of Angiotensin II Receptor Antagonist Business (2017-2022)
    Figure 74. Sun Pharmaceutical Revenue Growth Rate in Non-Peptide Drugs of Angiotensin II Receptor Antagonist Business (2017-2022)
    Figure 75. Mylan Revenue Growth Rate in Non-Peptide Drugs of Angiotensin II Receptor Antagonist Business (2017-2022)
    Figure 76. Alembic Pharmaceuticals Revenue Growth Rate in Non-Peptide Drugs of Angiotensin II Receptor Antagonist Business (2017-2022)
    Figure 77. Lupin Revenue Growth Rate in Non-Peptide Drugs of Angiotensin II Receptor Antagonist Business (2017-2022)
    Figure 78. Aurobindo Pharma Revenue Growth Rate in Non-Peptide Drugs of Angiotensin II Receptor Antagonist Business (2017-2022)
    Figure 79. Amneal Pharmaceuticals Revenue Growth Rate in Non-Peptide Drugs of Angiotensin II Receptor Antagonist Business (2017-2022)
    Figure 80. Boehringer Ingelheim Revenue Growth Rate in Non-Peptide Drugs of Angiotensin II Receptor Antagonist Business (2017-2022)
    Figure 81. Bottom-up and Top-down Approaches for This Report
    Figure 82. Data Triangulation
    Figure 83. Key Executives Interviewed